Gulf Pharmaceutical Industries (Julphar) has unveiled its Strategy 2030, which will see its revenues triple while it penetrates new territories and top pharma regions and launches more than 100 new products between 2022 and 2030.
DUBAI: Gulf Pharmaceutical Industries Julphar has announced its Strategy 2030, an effort to drive transformation that will contribute to higher shareholder returns. According to the Emirates News Agency, WAM, the company is on track to deliver revenue growth from its legacy products, and plans to launch over 100 new products between 2022 and 2030. It will leverage its in-house